Amgen financials
$423.64+1.32%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.75B | $33.42B | $28.19B | $26.32B | $25.98B | $25.42B | $23.36B | $23.75B | $22.85B | $22.99B |
| Gross profit | $24.71B | $20.57B | $19.74B | $19.92B | $19.52B | $19.27B | $19.01B | $19.65B | $18.78B | $18.83B |
| Gross margin | 67.2% | 61.5% | 70.0% | 75.7% | 75.2% | 75.8% | 81.4% | 82.7% | 82.2% | 81.9% |
| Operating income | $9.08B | $7.26B | $7.90B | $9.57B | $7.64B | $9.14B | $9.67B | $10.26B | $9.97B | $9.79B |
| Net income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B | $7.26B | $7.84B | $8.39B | $1.98B | $7.72B |
| Net margin | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% | 28.6% | 33.6% | 35.3% | 8.7% | 33.6% |
| Diluted EPS | $14.23 | $7.56 | $12.49 | $12.11 | $10.28 | $12.31 | $12.88 | $12.62 | $2.69 | $10.24 |
| EBITDA | $14.25B | $12.85B | $11.97B | $12.98B | $12.54B | $12.74B | $11.88B | $12.21B | $11.93B | $11.90B |
| Operating cash flow | $9.96B | $11.49B | $8.47B | $9.72B | $9.26B | $10.50B | $9.15B | $11.30B | $11.18B | $10.35B |
| Free cash flow | $8.10B | $10.39B | $7.36B | $8.79B | $8.38B | $9.89B | $8.53B | $10.56B | $10.51B | $9.62B |
| Diluted shares | 542.0M | 541.0M | 538.0M | 541.0M | 573.0M | 590.0M | 609.0M | 665.0M | 735.0M | 754.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.13B | $11.97B | $10.94B | $7.63B | $7.99B | $6.27B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $1.68B | $48.0M | $4.38B |
| Total debt | $54.60B | $60.10B | $64.61B | $38.95B | $33.31B | $32.99B |
| Total assets | $90.59B | $91.84B | $97.15B | $65.12B | $61.16B | $62.95B |
| Total liabilities | $81.93B | $85.96B | $90.92B | $61.46B | $54.47B | $53.54B |
| Shareholders' equity | $8.66B | $5.88B | $6.23B | $3.66B | $6.70B | $9.41B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology